Expert Interview
Examining the market potential of AbbVie's EPKINLY® (epcoritamab-bysp) for relapsed/refractory follicular lymphoma
Ticker(s): ABBVInstitution: Northwest Cancer Centers
- Hematologist/Oncologist and Research Director at Northwest Cancer Centers
- Manages 50+ patients yearly with follicular lymphoma
- Clinical interest in benign and malignant hematology and a research interest in the outcomes of sequential immunotherapies
On a scale of 1-10, 10 being extremely excited, where would you rate your level of excitement for this drug?
Added By: ben_adminWhat are your initial thoughts on Epkinly and its mechanism of action?
Added By: ben_adminPlease describe your clinical practice. How many patients with follicular lymphoma do you currently manage?
Added By: ben_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
